ºÝºÝߣshows by User: MMSHoldings1 / http://www.slideshare.net/images/logo.gif ºÝºÝߣshows by User: MMSHoldings1 / Mon, 26 Jun 2023 06:07:57 GMT ºÝºÝߣShare feed for ºÝºÝߣshows by User: MMSHoldings1 EU CTR Compliance and Success Navigating Updates and Preparing Submissions for the EU CTIS Portal.pptx /slideshow/eu-ctr-compliance-and-success-navigating-updates-and-preparing-submissions-for-the-eu-ctis-portalpptx/258629910 euctrcomplianceandsuccessnavigatingupdatesandpreparingsubmissionsfortheeuctisportal-230626060757-dbf1a89d
As of January 31, 2023, Sponsors are required to submit all new trial applications for authorization in the European Union through the Clinical Trial Information System (CTIS) in compliance with the new European Union Clinical Trials Regulation (EU CTR). With the new regulation, Sponsors are seeking guidance with questions such as: what types of documents to include, processes, timelines, and how to protect confidential information, among others. Not fully understanding the process could result in releasing unprotected data or withdrawing the application due to unmet deadlines and requirements. https://info.mmsholdings.com/eu-ctr-compliance-success-updates-submissions-for-eu-ctis-portal ]]>
As of January 31, 2023, Sponsors are required to submit all new trial applications for authorization in the European Union through the Clinical Trial Information System (CTIS) in compliance with the new European Union Clinical Trials Regulation (EU CTR). With the new regulation, Sponsors are seeking guidance with questions such as: what types of documents to include, processes, timelines, and how to protect confidential information, among others. Not fully understanding the process could result in releasing unprotected data or withdrawing the application due to unmet deadlines and requirements. https://info.mmsholdings.com/eu-ctr-compliance-success-updates-submissions-for-eu-ctis-portal ]]> Mon, 26 Jun 2023 06:07:57 GMT /slideshow/eu-ctr-compliance-and-success-navigating-updates-and-preparing-submissions-for-the-eu-ctis-portalpptx/258629910 MMSHoldings1@slideshare.net(MMSHoldings1) EU CTR Compliance and Success Navigating Updates and Preparing Submissions for the EU CTIS Portal.pptx MMSHoldings1 As of January 31, 2023, Sponsors are required to submit all new trial applications for authorization in the European Union through the Clinical Trial Information System (CTIS) in compliance with the new European Union Clinical Trials Regulation (EU CTR). With the new regulation, Sponsors are seeking guidance with questions such as: what types of documents to include, processes, timelines, and how to protect confidential information, among others. Not fully understanding the process could result in releasing unprotected data or withdrawing the application due to unmet deadlines and requirements. https://info.mmsholdings.com/eu-ctr-compliance-success-updates-submissions-for-eu-ctis-portal <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/euctrcomplianceandsuccessnavigatingupdatesandpreparingsubmissionsfortheeuctisportal-230626060757-dbf1a89d-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> As of January 31, 2023, Sponsors are required to submit all new trial applications for authorization in the European Union through the Clinical Trial Information System (CTIS) in compliance with the new European Union Clinical Trials Regulation (EU CTR). With the new regulation, Sponsors are seeking guidance with questions such as: what types of documents to include, processes, timelines, and how to protect confidential information, among others. Not fully understanding the process could result in releasing unprotected data or withdrawing the application due to unmet deadlines and requirements. https://info.mmsholdings.com/eu-ctr-compliance-success-updates-submissions-for-eu-ctis-portal
EU CTR Compliance and Success Navigating Updates and Preparing Submissions for the EU CTIS Portal.pptx from MMS Holdings
]]> 614 0 https://cdn.slidesharecdn.com/ss_thumbnails/euctrcomplianceandsuccessnavigatingupdatesandpreparingsubmissionsfortheeuctisportal-230626060757-dbf1a89d-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 How to Submit Non-Clinical Data to CBER Using SEND : Understanding New FDA Requirements.pptx /slideshow/how-to-submit-nonclinical-data-to-cber-using-send-understanding-new-fda-requirementspptx/256292233 howtosubmitnon-clinicaldatatocberusingsendunderstandingnewfdarequirements-230307163228-a0fd0005
What You Will Learn The FDA’s CBER will begin requiring electronic submissions of nonclinical data to be submitted using the 3.1 and 3.1.1 versions of CDISC SENDIG on March 15th, 2023. With these requirements taking effect soon, Sponsors need to understand how to meet the new rules and regulations provided by SEND, as failing to meet them could result in FDA refusal. In this webinar, a cross-functional team of statistical programmers and regulatory experts will share actionable insights to help study teams prepare for the new requirements. Attendees will learn how to: Understand nonclinical study data submissions to CDER and CBER Differentiate biologics from drug submission in non-clinical studies Prepare for this change to ensure a successful submission. Solve the challenges of a SEND package Ensure compliance with both SEND 3.1 and 3.1.1 for submission of nonclinical data to CDER and CBERHo Separate SEND IG DART 1.1 from SEND IG Manage legacy studies and studies that already meet requirements Differentiate between submission packages Use the FDA’s data standard catalog, technical conformance guide and controlled terminology Who Will Benefit from Attending? Regulatory Affairs and Submissions Professionals Pharmaceutical Data and Programming Professionals Nonclinical/Preclinical Development Professionals]]>
What You Will Learn The FDA’s CBER will begin requiring electronic submissions of nonclinical data to be submitted using the 3.1 and 3.1.1 versions of CDISC SENDIG on March 15th, 2023. With these requirements taking effect soon, Sponsors need to understand how to meet the new rules and regulations provided by SEND, as failing to meet them could result in FDA refusal. In this webinar, a cross-functional team of statistical programmers and regulatory experts will share actionable insights to help study teams prepare for the new requirements. Attendees will learn how to: Understand nonclinical study data submissions to CDER and CBER Differentiate biologics from drug submission in non-clinical studies Prepare for this change to ensure a successful submission. Solve the challenges of a SEND package Ensure compliance with both SEND 3.1 and 3.1.1 for submission of nonclinical data to CDER and CBERHo Separate SEND IG DART 1.1 from SEND IG Manage legacy studies and studies that already meet requirements Differentiate between submission packages Use the FDA’s data standard catalog, technical conformance guide and controlled terminology Who Will Benefit from Attending? Regulatory Affairs and Submissions Professionals Pharmaceutical Data and Programming Professionals Nonclinical/Preclinical Development Professionals]]> Tue, 07 Mar 2023 16:32:28 GMT /slideshow/how-to-submit-nonclinical-data-to-cber-using-send-understanding-new-fda-requirementspptx/256292233 MMSHoldings1@slideshare.net(MMSHoldings1) How to Submit Non-Clinical Data to CBER Using SEND : Understanding New FDA Requirements.pptx MMSHoldings1 What You Will Learn The FDA’s CBER will begin requiring electronic submissions of nonclinical data to be submitted using the 3.1 and 3.1.1 versions of CDISC SENDIG on March 15th, 2023. With these requirements taking effect soon, Sponsors need to understand how to meet the new rules and regulations provided by SEND, as failing to meet them could result in FDA refusal. In this webinar, a cross-functional team of statistical programmers and regulatory experts will share actionable insights to help study teams prepare for the new requirements. Attendees will learn how to: Understand nonclinical study data submissions to CDER and CBER Differentiate biologics from drug submission in non-clinical studies Prepare for this change to ensure a successful submission. Solve the challenges of a SEND package Ensure compliance with both SEND 3.1 and 3.1.1 for submission of nonclinical data to CDER and CBERHo Separate SEND IG DART 1.1 from SEND IG Manage legacy studies and studies that already meet requirements Differentiate between submission packages Use the FDA’s data standard catalog, technical conformance guide and controlled terminology Who Will Benefit from Attending? Regulatory Affairs and Submissions Professionals Pharmaceutical Data and Programming Professionals Nonclinical/Preclinical Development Professionals <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/howtosubmitnon-clinicaldatatocberusingsendunderstandingnewfdarequirements-230307163228-a0fd0005-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> What You Will Learn The FDA’s CBER will begin requiring electronic submissions of nonclinical data to be submitted using the 3.1 and 3.1.1 versions of CDISC SENDIG on March 15th, 2023. With these requirements taking effect soon, Sponsors need to understand how to meet the new rules and regulations provided by SEND, as failing to meet them could result in FDA refusal. In this webinar, a cross-functional team of statistical programmers and regulatory experts will share actionable insights to help study teams prepare for the new requirements. Attendees will learn how to: Understand nonclinical study data submissions to CDER and CBER Differentiate biologics from drug submission in non-clinical studies Prepare for this change to ensure a successful submission. Solve the challenges of a SEND package Ensure compliance with both SEND 3.1 and 3.1.1 for submission of nonclinical data to CDER and CBERHo Separate SEND IG DART 1.1 from SEND IG Manage legacy studies and studies that already meet requirements Differentiate between submission packages Use the FDA’s data standard catalog, technical conformance guide and controlled terminology Who Will Benefit from Attending? Regulatory Affairs and Submissions Professionals Pharmaceutical Data and Programming Professionals Nonclinical/Preclinical Development Professionals
How to Submit Non-Clinical Data to CBER Using SEND : Understanding New FDA Requirements.pptx from MMS Holdings
]]> 869 0 https://cdn.slidesharecdn.com/ss_thumbnails/howtosubmitnon-clinicaldatatocberusingsendunderstandingnewfdarequirements-230307163228-a0fd0005-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Data Management Considerations for Decentralized Clinical Trial Implementation /slideshow/data-management-considerations-for-decentralized-clinical-trial-implementation/253223624 decentralizedclinicaltrialswebinar-220928094347-0865c96f
In this webinar, MMS data managers will review the basics of decentralized clinical trials and expand on how to address challenges that may arise when working on a DCT. https://info.mmsholdings.com/dct-webinar-sep ]]>
In this webinar, MMS data managers will review the basics of decentralized clinical trials and expand on how to address challenges that may arise when working on a DCT. https://info.mmsholdings.com/dct-webinar-sep ]]> Wed, 28 Sep 2022 09:43:47 GMT /slideshow/data-management-considerations-for-decentralized-clinical-trial-implementation/253223624 MMSHoldings1@slideshare.net(MMSHoldings1) Data Management Considerations for Decentralized Clinical Trial Implementation MMSHoldings1 In this webinar, MMS data managers will review the basics of decentralized clinical trials and expand on how to address challenges that may arise when working on a DCT. https://info.mmsholdings.com/dct-webinar-sep <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/decentralizedclinicaltrialswebinar-220928094347-0865c96f-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> In this webinar, MMS data managers will review the basics of decentralized clinical trials and expand on how to address challenges that may arise when working on a DCT. https://info.mmsholdings.com/dct-webinar-sep
Data Management Considerations for Decentralized Clinical Trial Implementation from MMS Holdings
]]> 268 0 https://cdn.slidesharecdn.com/ss_thumbnails/decentralizedclinicaltrialswebinar-220928094347-0865c96f-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Natural Language Processing to Curate Unstructured Electronic Health Records /slideshow/natural-language-processing-to-curate-unstructured-electronic-health-records/252360081 icodanlpwebinar26jul2022-220729120611-9eec8560
This presentation provides an overview of Natural Language Processing (NLP), an Artificial Intelligence technique that can be used to curate unstructured medical records. We will see NLP in action as part of the ICODA Grand Challenges ‘PRIEST’ project (Pandemic Respiratory Infection Emergency System Triage) Study for Low and Middle-Income Countries as a case study. Watch full webinar - https://info.mmsholdings.com/natural-language-processing-webinar-july-2022]]>
This presentation provides an overview of Natural Language Processing (NLP), an Artificial Intelligence technique that can be used to curate unstructured medical records. We will see NLP in action as part of the ICODA Grand Challenges ‘PRIEST’ project (Pandemic Respiratory Infection Emergency System Triage) Study for Low and Middle-Income Countries as a case study. Watch full webinar - https://info.mmsholdings.com/natural-language-processing-webinar-july-2022]]> Fri, 29 Jul 2022 12:06:10 GMT /slideshow/natural-language-processing-to-curate-unstructured-electronic-health-records/252360081 MMSHoldings1@slideshare.net(MMSHoldings1) Natural Language Processing to Curate Unstructured Electronic Health Records MMSHoldings1 This presentation provides an overview of Natural Language Processing (NLP), an Artificial Intelligence technique that can be used to curate unstructured medical records. We will see NLP in action as part of the ICODA Grand Challenges ‘PRIEST’ project (Pandemic Respiratory Infection Emergency System Triage) Study for Low and Middle-Income Countries as a case study. Watch full webinar - https://info.mmsholdings.com/natural-language-processing-webinar-july-2022 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/icodanlpwebinar26jul2022-220729120611-9eec8560-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> This presentation provides an overview of Natural Language Processing (NLP), an Artificial Intelligence technique that can be used to curate unstructured medical records. We will see NLP in action as part of the ICODA Grand Challenges ‘PRIEST’ project (Pandemic Respiratory Infection Emergency System Triage) Study for Low and Middle-Income Countries as a case study. Watch full webinar - https://info.mmsholdings.com/natural-language-processing-webinar-july-2022
Natural Language Processing to Curate Unstructured Electronic Health Records from MMS Holdings
]]> 154 0 https://cdn.slidesharecdn.com/ss_thumbnails/icodanlpwebinar26jul2022-220729120611-9eec8560-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 How to Create Fit-For-Purpose Clinical Study Reports for Successful Submissions /slideshow/how-to-create-fitforpurpose-clinical-study-reports-for-successful-submissions/251996898 csrforasuccessfulsubmission-howtocreatefit-for-purposeclinicalstudyreportsforsuccessfulsubmissions-220616070543-897b7b27
A clinical study report (CSR) is an essential building block of a clinical submission. The ICH and FDA provide guidance for the structure and content of CSRs and instances when an abbreviated or synoptic CSR format should be used in place of a full CSR format, depending on the role of the CSR in a submission.]]>
A clinical study report (CSR) is an essential building block of a clinical submission. The ICH and FDA provide guidance for the structure and content of CSRs and instances when an abbreviated or synoptic CSR format should be used in place of a full CSR format, depending on the role of the CSR in a submission.]]> Thu, 16 Jun 2022 07:05:43 GMT /slideshow/how-to-create-fitforpurpose-clinical-study-reports-for-successful-submissions/251996898 MMSHoldings1@slideshare.net(MMSHoldings1) How to Create Fit-For-Purpose Clinical Study Reports for Successful Submissions MMSHoldings1 A clinical study report (CSR) is an essential building block of a clinical submission. The ICH and FDA provide guidance for the structure and content of CSRs and instances when an abbreviated or synoptic CSR format should be used in place of a full CSR format, depending on the role of the CSR in a submission. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/csrforasuccessfulsubmission-howtocreatefit-for-purposeclinicalstudyreportsforsuccessfulsubmissions-220616070543-897b7b27-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> A clinical study report (CSR) is an essential building block of a clinical submission. The ICH and FDA provide guidance for the structure and content of CSRs and instances when an abbreviated or synoptic CSR format should be used in place of a full CSR format, depending on the role of the CSR in a submission.
How to Create Fit-For-Purpose Clinical Study Reports for Successful Submissions from MMS Holdings
]]> 997 0 https://cdn.slidesharecdn.com/ss_thumbnails/csrforasuccessfulsubmission-howtocreatefit-for-purposeclinicalstudyreportsforsuccessfulsubmissions-220616070543-897b7b27-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Strategies for Navigating ICH E9(R1) Webinar slides /slideshow/strategies-for-navigating-ich-e9r1may-3pptx/251731025 strategiesfornavigatingiche9r1may3-220506122240-ab0647cf
https://info.mmsholdings.com/strategies-for-navigating-ich-e9-webinar?hsLang=en The ICH E9(R1) Addendum on 'Estimands and Sensitivity Analysis in Clinical Trials' introduced a framework to align planning, design, conduct, analysis, and interpretation of clinical trials. When defining the clinical question of interest, clarity is needed about 'intercurrent events' that affect either the interpretation or the existence of the measurements associated with the clinical question of interest, such as discontinuation of assigned treatment, use of an additional or alternative treatment and terminal events such as death. The description of an estimand should reflect the clinical question of interest in respect of these intercurrent events, and the Addendum introduces strategies to reflect different questions of interest that might be posed. The choice of strategies can influence how more conventional attributes of a trial are reflected when describing the clinical question, for example the treatments, population or the variable (endpoint) of interest. ]]>
https://info.mmsholdings.com/strategies-for-navigating-ich-e9-webinar?hsLang=en The ICH E9(R1) Addendum on 'Estimands and Sensitivity Analysis in Clinical Trials' introduced a framework to align planning, design, conduct, analysis, and interpretation of clinical trials. When defining the clinical question of interest, clarity is needed about 'intercurrent events' that affect either the interpretation or the existence of the measurements associated with the clinical question of interest, such as discontinuation of assigned treatment, use of an additional or alternative treatment and terminal events such as death. The description of an estimand should reflect the clinical question of interest in respect of these intercurrent events, and the Addendum introduces strategies to reflect different questions of interest that might be posed. The choice of strategies can influence how more conventional attributes of a trial are reflected when describing the clinical question, for example the treatments, population or the variable (endpoint) of interest. ]]> Fri, 06 May 2022 12:22:40 GMT /slideshow/strategies-for-navigating-ich-e9r1may-3pptx/251731025 MMSHoldings1@slideshare.net(MMSHoldings1) Strategies for Navigating ICH E9(R1) Webinar slides MMSHoldings1 https://info.mmsholdings.com/strategies-for-navigating-ich-e9-webinar?hsLang=en The ICH E9(R1) Addendum on 'Estimands and Sensitivity Analysis in Clinical Trials' introduced a framework to align planning, design, conduct, analysis, and interpretation of clinical trials. When defining the clinical question of interest, clarity is needed about 'intercurrent events' that affect either the interpretation or the existence of the measurements associated with the clinical question of interest, such as discontinuation of assigned treatment, use of an additional or alternative treatment and terminal events such as death. The description of an estimand should reflect the clinical question of interest in respect of these intercurrent events, and the Addendum introduces strategies to reflect different questions of interest that might be posed. The choice of strategies can influence how more conventional attributes of a trial are reflected when describing the clinical question, for example the treatments, population or the variable (endpoint) of interest. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/strategiesfornavigatingiche9r1may3-220506122240-ab0647cf-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> https://info.mmsholdings.com/strategies-for-navigating-ich-e9-webinar?hsLang=en The ICH E9(R1) Addendum on &#39;Estimands and Sensitivity Analysis in Clinical Trials&#39; introduced a framework to align planning, design, conduct, analysis, and interpretation of clinical trials. When defining the clinical question of interest, clarity is needed about &#39;intercurrent events&#39; that affect either the interpretation or the existence of the measurements associated with the clinical question of interest, such as discontinuation of assigned treatment, use of an additional or alternative treatment and terminal events such as death. The description of an estimand should reflect the clinical question of interest in respect of these intercurrent events, and the Addendum introduces strategies to reflect different questions of interest that might be posed. The choice of strategies can influence how more conventional attributes of a trial are reflected when describing the clinical question, for example the treatments, population or the variable (endpoint) of interest.
Strategies for Navigating ICH E9(R1) Webinar slides from MMS Holdings
]]> 793 0 https://cdn.slidesharecdn.com/ss_thumbnails/strategiesfornavigatingiche9r1may3-220506122240-ab0647cf-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Insights and Trends from 2021 FDA GCP Inspections.pptx /slideshow/insights-and-trends-from-2021-fda-gcp-inspectionspptx/251476484 insightsandtrendsfrom2021fdagcpinspections-220330175158
MMS Holdings Expert Insights webinar]]>
MMS Holdings Expert Insights webinar]]> Wed, 30 Mar 2022 17:51:57 GMT /slideshow/insights-and-trends-from-2021-fda-gcp-inspectionspptx/251476484 MMSHoldings1@slideshare.net(MMSHoldings1) Insights and Trends from 2021 FDA GCP Inspections.pptx MMSHoldings1 MMS Holdings Expert Insights webinar <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/insightsandtrendsfrom2021fdagcpinspections-220330175158-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> MMS Holdings Expert Insights webinar
Insights and Trends from 2021 FDA GCP Inspections.pptx from MMS Holdings
]]> 490 0 https://cdn.slidesharecdn.com/ss_thumbnails/insightsandtrendsfrom2021fdagcpinspections-220330175158-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 How to Use Machine Learning in Clinical Research Right Now_.pptx /slideshow/how-to-use-machine-learning-in-clinical-research-right-nowpptx/251419016 howtousemachinelearninginclinicalresearchrightnow-220324154736
MMS Holdings Expert Insights webinar]]>
MMS Holdings Expert Insights webinar]]> Thu, 24 Mar 2022 15:47:35 GMT /slideshow/how-to-use-machine-learning-in-clinical-research-right-nowpptx/251419016 MMSHoldings1@slideshare.net(MMSHoldings1) How to Use Machine Learning in Clinical Research Right Now_.pptx MMSHoldings1 MMS Holdings Expert Insights webinar <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/howtousemachinelearninginclinicalresearchrightnow-220324154736-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> MMS Holdings Expert Insights webinar
How to Use Machine Learning in Clinical Research Right Now_.pptx from MMS Holdings
]]> 620 0 https://cdn.slidesharecdn.com/ss_thumbnails/howtousemachinelearninginclinicalresearchrightnow-220324154736-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Evolving Your FSP Relationships to Achieve Maximum Return.pptx /slideshow/evolving-your-fsp-relationships-to-achieve-maximum-returnpptx/251418956 evolvingyourfsprelationshipstoachievemaximumreturn-220324153527
MMS Holdings Expert Insights webinar]]>
MMS Holdings Expert Insights webinar]]> Thu, 24 Mar 2022 15:35:27 GMT /slideshow/evolving-your-fsp-relationships-to-achieve-maximum-returnpptx/251418956 MMSHoldings1@slideshare.net(MMSHoldings1) Evolving Your FSP Relationships to Achieve Maximum Return.pptx MMSHoldings1 MMS Holdings Expert Insights webinar <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/evolvingyourfsprelationshipstoachievemaximumreturn-220324153527-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> MMS Holdings Expert Insights webinar
Evolving Your FSP Relationships to Achieve Maximum Return.pptx from MMS Holdings
]]> 126 0 https://cdn.slidesharecdn.com/ss_thumbnails/evolvingyourfsprelationshipstoachievemaximumreturn-220324153527-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 IND and CTA Webinar slides.pptx /slideshow/ind-and-cta-webinar-slidespptx/251418877 indandctawebinarslides-220324151538
MMS Holdings Expert Insights webinar]]>
MMS Holdings Expert Insights webinar]]> Thu, 24 Mar 2022 15:15:37 GMT /slideshow/ind-and-cta-webinar-slidespptx/251418877 MMSHoldings1@slideshare.net(MMSHoldings1) IND and CTA Webinar slides.pptx MMSHoldings1 MMS Holdings Expert Insights webinar <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/indandctawebinarslides-220324151538-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> MMS Holdings Expert Insights webinar
IND and CTA Webinar slides.pptx from MMS Holdings
]]> 1585 0 https://cdn.slidesharecdn.com/ss_thumbnails/indandctawebinarslides-220324151538-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 EU Clinical Regulation Webinar ºÝºÝߣ Deck.pptx /slideshow/eu-clinical-regulation-webinar-slide-deckpptx/251418765 euclinicalregulationwebinarslidedeck-220324145156
MMS Holdings Expert Insights webinar]]>
MMS Holdings Expert Insights webinar]]> Thu, 24 Mar 2022 14:51:56 GMT /slideshow/eu-clinical-regulation-webinar-slide-deckpptx/251418765 MMSHoldings1@slideshare.net(MMSHoldings1) EU Clinical Regulation Webinar ºÝºÝߣ Deck.pptx MMSHoldings1 MMS Holdings Expert Insights webinar <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/euclinicalregulationwebinarslidedeck-220324145156-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> MMS Holdings Expert Insights webinar
EU Clinical Regulation Webinar ºÝºÝߣ Deck.pptx from MMS Holdings
]]> 465 0 https://cdn.slidesharecdn.com/ss_thumbnails/euclinicalregulationwebinarslidedeck-220324145156-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 The Blueprint for Success for Effective and Efficient Clinical Protocols.pptx /slideshow/the-blueprint-for-success-for-effective-and-efficient-clinical-protocolspptx/251418617 theblueprintforsuccessforeffectiveandefficientclinicalprotocols-220324142751
MMS Holdings Expert Insights Webinar]]>
MMS Holdings Expert Insights Webinar]]> Thu, 24 Mar 2022 14:27:50 GMT /slideshow/the-blueprint-for-success-for-effective-and-efficient-clinical-protocolspptx/251418617 MMSHoldings1@slideshare.net(MMSHoldings1) The Blueprint for Success for Effective and Efficient Clinical Protocols.pptx MMSHoldings1 MMS Holdings Expert Insights Webinar <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/theblueprintforsuccessforeffectiveandefficientclinicalprotocols-220324142751-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> MMS Holdings Expert Insights Webinar
The Blueprint for Success for Effective and Efficient Clinical Protocols.pptx from MMS Holdings
]]> 198 0 https://cdn.slidesharecdn.com/ss_thumbnails/theblueprintforsuccessforeffectiveandefficientclinicalprotocols-220324142751-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Rare Disease Series ºÝºÝߣ Deck Part 1.pptx /slideshow/rare-disease-series-slide-deck-part-1pptx/251411244 rarediseaseseriesslidedeck-220323205518
MMS Holdings Rare Disease Webinar #1]]>
MMS Holdings Rare Disease Webinar #1]]> Wed, 23 Mar 2022 20:55:18 GMT /slideshow/rare-disease-series-slide-deck-part-1pptx/251411244 MMSHoldings1@slideshare.net(MMSHoldings1) Rare Disease Series ºÝºÝߣ Deck Part 1.pptx MMSHoldings1 MMS Holdings Rare Disease Webinar #1 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/rarediseaseseriesslidedeck-220323205518-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> MMS Holdings Rare Disease Webinar #1
Rare Disease Series ºÝºÝߣ Deck Part 1.pptx from MMS Holdings
]]> 666 0 https://cdn.slidesharecdn.com/ss_thumbnails/rarediseaseseriesslidedeck-220323205518-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://public.slidesharecdn.com/v2/images/profile-picture.png https://cdn.slidesharecdn.com/ss_thumbnails/euctrcomplianceandsuccessnavigatingupdatesandpreparingsubmissionsfortheeuctisportal-230626060757-dbf1a89d-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/eu-ctr-compliance-and-success-navigating-updates-and-preparing-submissions-for-the-eu-ctis-portalpptx/258629910 EU CTR Compliance and ... https://cdn.slidesharecdn.com/ss_thumbnails/howtosubmitnon-clinicaldatatocberusingsendunderstandingnewfdarequirements-230307163228-a0fd0005-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/how-to-submit-nonclinical-data-to-cber-using-send-understanding-new-fda-requirementspptx/256292233 How to Submit Non-Clin... https://cdn.slidesharecdn.com/ss_thumbnails/decentralizedclinicaltrialswebinar-220928094347-0865c96f-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/data-management-considerations-for-decentralized-clinical-trial-implementation/253223624 Data Management Consid...